Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 19/20 | 1.00 |
| ▸ | PDE4A | P27815 | 17/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18644797 | 0.90 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL18644772 | 0.90 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL18644769 | 0.89 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL17508935 | 0.86 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL18644800 | 0.85 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL18644775 | 0.85 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL18644753 | 0.85 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL17492382 | 0.85 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL17492374 | 0.85 | PDE4D (0.76) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL17508925 | 0.84 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077269-B2 | Imidazopyridazine compounds | PFIZER INC. (US) | 2018-09-18 | — | — | US | claimed |
| US-20170145022-A1 | Imidazopyridazine Compounds | PFIZER INC. (US) | 2017-05-25 | — | — | US | claimed |
| US-10669279-B2 | Imidazopyridazine compounds | PFIZER INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190322674-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | PFIZER (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3177624-B1 | IMIDAZOPYRIDAZINE COMPOUNDS | PFIZER (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10077269-B2 | Imidazopyridazine compounds | PFIZER INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20170145022-A1 | Imidazopyridazine Compounds | PFIZER INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145022-A1 | Imidazopyridazine Compounds | PFIZER INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145022-A1 | Imidazopyridazine Compounds | PFIZER INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9598421-B2 | Imidazopyridazine compounds | PFIZER INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598421-B2 | Imidazopyridazine compounds | PFIZER INC. (US) | 2017-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077269-B2 | Imidazopyridazine compounds | CYP3A5, QDPR, CYP3A7 | PDE4B 206/4885PDE4D 443/4885PDE4A 306/4885 |
| US-20170145022-A1 | Imidazopyridazine Compounds | CYP3A5, QDPR, CYP3A7 | PDE4B 206/4885PDE4D 443/4885PDE4A 306/4885 |
| US-20190322674-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | CYP3A5, QDPR, CYP3A7 | PDE4B 206/4885PDE4D 443/4885PDE4A 306/4885 |
| US-10669279-B2 | Imidazopyridazine compounds | CYP3A5, QDPR, CYP3A7 | PDE4B 206/4885PDE4D 443/4885PDE4A 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.